ACTG175

ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with 
combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human 
immunodeficiency virus type I whose CD4 cell counts were between 200 and 500 per cubic millimeter.

datasets

The package performs estimation and testing of the
        treatment effect in a 2-group randomized clinical trial with a
        quantitative or dichotomous endpoint. The method is a special
        case of Robins, Rotnitzky, and Zhao (1994, JASA). It improves
        efficiency by leveraging baseline predictors of the endpoint.
        The method uses inverse probability weighting to provide
        unbiased estimation when the endpoint is missing at random.

ACTG175: AIDS Clinical Trials Group Study 175

Description

Usage

Arguments

Details

References